New 'Living Drug' trial targets Tough-to-Treat stomach and colon cancers
NCT ID NCT06055439
Summary
This study is testing a new personalized cell therapy called CHM-2101 for people with advanced stomach, colon, or neuroendocrine cancers that have come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back into the patient. The main goals are to find a safe dose and see if this therapy can shrink tumors and control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Conditions
Explore the condition pages connected to this study.